Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study showed that androgenetic alopecia independently predicted higher mortality from diabetes and heart disease in both men and women, with increased rates in individuals with moderate or severe AGA.

AGA is a genetic, hormonal hair loss treated with finasteride, minoxidil, and supplements, but new compounds are being developed.

This article discusses approaches to diagnosing and treating androgenetic alopecia but reports no new clinical results.

This article discusses the challenges of treating androgenetic alopecia due to limited approved medications, potential side effects, and unmet expectations and reports no new clinical results.

PGD2 stops hair growth and is higher in bald men with AGA.

This article reviews various aspects of androgenetic alopecia, from its historical perceptions to current understanding and treatments, without providing new clinical results.

This article reviews androgenetic alopecia, detailing its genetic and hormonal causes, clinical presentations, diagnosis, and treatment options, but it reports no new clinical findings.

This guideline reviews the diagnosis of androgenetic alopecia and offers expert consensus recommendations tailored to males, females, and adolescents, but reports no new clinical results.

This article reviews the causes and pattern of androgenetic alopecia and reports no new research findings.

DMG-Na may help reduce hair loss and improve hair growth, but more research is needed.

Androgenetic alopecia (AGA) is a common, hereditary hair loss condition that can be slowed but not permanently reversed with available therapies.

In this study, several dermoscopic features such as hair diameter diversity, brown peripilar sign, and focal atrichia were frequently observed in both male and female androgenetic alopecia patients, highlighting these as potential AGA indicators.

This study of androgenic alopecia patients reports that stress was associated with AGA in both men and women, with notable findings differing by gender, age, and AGA type.

AGA treated with finasteride, minoxidil, and hair transplantation.

This study investigated AGA professionals' perspectives and found that 42% were misled by commercial influences, underestimated these biases' extent, and faced ethical challenges in treatment due to societal pressures and misinformation, highlighting a need for evidence-based guidance and research scrutiny tools.

In this study, a newly designed protein degrader targeting androgen receptors showed promise in reversing hair regrowth inhibition in a mouse model of androgenetic alopecia, suggesting potential as a novel and safe treatment strategy.

This article reviews androgenetic alopecia and its effects but reports no new clinical results, highlighting that current treatments offer only temporary therapeutic benefits.

This review discusses pediatric androgenetic alopecia, emphasizing the diagnostic process and outlining potential treatments, but reports no new clinical results.

This study found that external application of DGD activates the Wnt/β-catenin signaling pathway, promoting hair follicle anagen phase entry, and is a more effective and safer treatment for androgenetic alopecia in mice compared to oral administration.

In this study, PGD2 was shown to increase testosterone production in human keratinocytes through reactive oxygen species, suggesting potential benefits of antioxidants like N-acetyl-cysteine for AGA patients.

Dermatologists should consider alpha-gal syndrome in patients with unexplained chronic skin issues.

This article reviews current diagnostic and treatment approaches for androgenetic alopecia but reports no new results, focusing on its progression and medical management options.

This review discusses treatments for androgenic alopecia, including minoxidil, finasteride, and hormonal therapies with antiandrogens, and reports no new clinical findings.

This case study reports that a heterozygous missense GJA1 mutation, p.Gly138Ser, in a 2-year-old boy with oculodentodigital syndrome primarily resulted in syndactyly, fifth finger hypoplasia, and hypotrichosis, without neurological or craniofacial abnormalities.

In this study, a novel AR protein degrader was shown to reverse DHT-induced hair regrowth delay in a mouse model of androgenetic alopecia, with minimal circulation and potential side effects.

This review discusses female androgenic alopecia, highlighting its potential difference from male androgenic alopecia and notes increased incidence, but reports no new clinical findings.

This review discusses recent advances in the understanding of androgenetic alopecia, focusing on genetic factors and new diagnostic and treatment approaches, but it does not provide new clinical results.

This study observed that inflammatory AIGA is associated with sweat duct inflammation and sweat coil atrophy, while non-inflammatory AIGA involves only sweat coil atrophy, suggesting distinct pathological features between the two.

This study reviews the interplay between endocrine factors and genetic predisposition in androgenetic alopecia, highlighting various treatment options, including new medical, surgical, and light-based therapies, though some remain relatively unexplored.

This review discusses the increased prevalence of androgenic alopecia in men and women, highlighting the limited FDA-approved treatment options, and reports no clinical results; the authors note adherence challenges due to prolonged drug use.